“What we need now are biomarkers to know if the medication is going to work or not,” says Park.
In this video, Chandler Park, MD, MSc, FACP, co-director, Genitourinary Clinical Trials at Norton Cancer Institute in Louisville, Kentucky, discusses the VISION study, which supported the FDA approval of lutetium 177 (177Lu-PSMA-617; lutetium Lu 177 vipivotide tetraxetan; Pluvicto) for patients with PSMA-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy. He also highlights the next steps with lutetium 177 in the prostate cancer paradigm.
We were very fortunate to participate in this clinical study called the VISION study. And in the VISION study, we have lutetium 177. And we were one of the leading enrollers for this study. It showed that for patients in the metastatic castration-resistant prostate cancer space who progressed on a taxane and an androgen pathway inhibitor—so the third-line setting—lutetium 177 is very effective. But now this treatment is going into earlier lines of treatment. There's a lot of studies right now, for instance, lutetium 177 with an androgen pathway inhibitor in the first-line metastatic castration-resistant space, and also lutetium 177 and all these other theranostic radioligand treatments are being explored in the metastatic hormone-sensitive space. And so these effective medications are moving into earlier lines of treatment.
What we need now are biomarkers to know if the medication is going to work or not. And so one of the studies that they showed at ASCO last year was called the TheraPstudy. And the TheraP study was a randomized study; it was an Australian study. It was a phase 2 study in which patients were randomized to cabazitaxel versus lutetium 177. And what they found is that in specific patients with PSMA SUVmean levels of 10 or higher, the odds of response to lutetium 177 were substantially higher.
The transcript has been edited for clarity.